Table 1. Baseline characteristics of included studies.
| Study | Country | Study design | Surgery method | Child-Pugh score A/B, n (%) | Cirrhosis, n (%) | HBV/HCV, n (%) |
|---|---|---|---|---|---|---|
| Dong et al. 2009 | China | RCT | Curative resection | 102/25 | 101 | 96/NR |
| Huang et al. 2013 | China | Retrospective | TACE+RFA | 150/24 (86/14) | 66 | 135/NR |
| Kawata et al. 1995 | Japan | RCT | Curative resection + adriamycin | NR | 14 | NR |
| Lee, et al. 2015 | Korea | RCT | Curative resection, RFA, or PEI | 226/0 | 146 | 192/23 |
| Pan et al. 2015 | China | Retrospective | Curative resection | NR | NR | 866/NR |
| Takayama et al. 2000 | Japan | RCT | Curative resection | 104/46 | 73 | 29/99 |
| Weng et al. 2008 | China | RCT | TACE+ RFA | 69/16 | NR | NR/NR |
| Xie et al. 2000 | China | RCT | Curative resection + TACE | NR | NR | NR |
| Xu et al. 2016 | China | RCT | Curative resection | 200/0 | 113 | 171/NR |
| Zhou et al. 1995 | China | RCT | Curative resection | NR | NR | NR/NR |
Abbreviations: AIT, adoptive immunotherapy; HBV, hepatitis B virus; HCV, hepatitis C virus; NR, not reported; PEI, percutaneous ethanol injection; RCT, randomized controlled trial; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.